Variant Summary
- Also known as
- PHE1174LEU,RS863225281
- HGVS
- NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A
- Variant Type(s)
- missense_variant
- Evidence Items
- 9
Evidence Level Distribution
Level C: 1Level D: 8
Evidence Items
Showing CIViC evidence rows where gene = ALK and variant = F1174L.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Lorlatinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | ALK Inhibitor TAE684 | 4 |
| D | Predictive | Supports | Resistance | Neuroblastoma | Crizotinib | 3 |
| C | Predictive | Does Not Support | Sensitivity/Response | Neuroblastoma | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | AZD3463 | 3 |
| D | Predictive | Supports | Resistance | Inflammatory Myofibroblastic Tumor | Crizotinib | 3 |
| D | Predictive | Supports | Resistance | Lung Non-small Cell Carcinoma | Crizotinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Alectinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Neuroblastoma | Crizotinib | 3 |